Associated Papers
Association between CYP2A6 genetic variants and serum concentrations of highly persistent OH-PCBs and their parent PCBs in humans.
Lyu Z et al.
Journal of Hazardous Materials, 2026
Characterisation of pharmacogenomic variation in the Shetland and Orkney Isles in Scotland.
Twesigomwe D et al.
Scientific Reports, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Waardenburg syndrome type 2 with a de novo variant of the SOX10 gene: a case report.
Li Y et al.
Bmc Medical Genomics, 2024
Whole exome sequencing identifies genetic markers of enterovirus susceptibility in East Asians.
Sung CC et al.
Frontiers in Microbiology, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.
El-Boraie A et al.
Clinical and Translational Science, 2022
Deciphering Structural Alterations Associated with Activity Reductions of Genetic Polymorphisms in Cytochrome P450 2A6 Using Molecular Dynamics Simulations.
Kato K et al.
International Journal of Molecular Sciences, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Variation in CYP2A6 Activity and Personalized Medicine.
Tanner JA et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
Bertholee D et al.
Clinical Pharmacokinetics, 2017
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Yamamiya I et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.
Wang TH et al.
The Aaps Journal, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM et al.
Pharmacology & Therapeutics, 2013
Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.
Djordjevic N et al.
Drug Metabolism and Pharmacokinetics, 2013
Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers.
Lin CY et al.
Thescientificworldjournal, 2013
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.
Preissner SC et al.
Plos One, 2013
Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S et al.
Biological & Pharmaceutical Bulletin, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Tanii H et al.
European Journal of Clinical Pharmacology, 2011
Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line.
Lee HJ et al.
Toxicological Research, 2011
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Tsunoda A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2011
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Chuah B et al.
Cancer Science, 2011
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T et al.
Oncology Reports, 2010
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Ishii Y et al.
Cancer Chemotherapy and Pharmacology, 2010
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
Al Koudsi N et al.
The Pharmacogenomics Journal, 2009
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J et al.
Pharmacogenetics and Genomics, 2009
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.
Zienolddiny S et al.
Carcinogenesis, 2008
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K et al.
Cancer Science, 2008
Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
Nakajima M
Current Opinion in Molecular Therapeutics, 2007
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Wall TL et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2007
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M et al.
Clinical Pharmacology and Therapeutics, 2006
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
Al Koudsi N et al.
European Journal of Clinical Pharmacology, 2006
Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms.
Minematsu N et al.
The European Respiratory Journal, 2006
Japanese single nucleotide polymorphism database for 267 possible drug-related genes.
Iida A et al.
Cancer Science, 2006
Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M et al.
Drug Metabolism and Pharmacokinetics, 2005
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC et al.
Pharmacogenetics and Genomics, 2005
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M et al.
Carcinogenesis, 2004